ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the 'Class Period'), of the important September 15, 2025 lead plaintiff deadline.
SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Capricor class action, go to https://rosenlegal.com/submit-form/?case_id=42281 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning deramiocel, Capricor's lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Further, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. The lawsuit alleges this caused shareholders to purchase Capricor's securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Capricor class action, go to https://rosenlegal.com/submit-form/?case_id=42281 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————-
Contact Information:
Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Where Will Nvidia Stock Be in 1 Year?
Key Points Nvidia stock has been in fine form over the past year, thanks to healthy demand for its AI chips. A closer look at the capital spending estimates of big tech companies suggests that Nvidia has room to deliver more upside over the next 12 months. The company should also get a nice shot in the arm by resuming its chip sales to Chinese customers, as it expects to be given permission to do. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) is the world's largest company, with a market cap around $4.4 trillion. It has reached this place thanks to its dominant position in the market for artificial intelligence (AI) chips that handle training and inference workloads in data centers. The booming demand for AI chips has helped Nvidia deliver outstanding growth over the past several quarters. Its terrific growth has led to healthy market gains of 68% in the past year as of market close Aug. 4, despite a difficult start to 2025. In fact, Nvidia stock's returns have easily outpaced the 18% gains clocked by the S&P 500 index during this same period. Investors, however, may be wondering whether Nvidia has the ability to sustain its momentum in the coming year, especially considering its huge market cap and high valuation. In this article, I will take a closer look at Nvidia's catalysts and see where the stock could be after a year. These developments suggest Nvidia has room for more upside Massive spending by cloud computing giants and governments around the globe has played a central role in driving Nvidia's outstanding revenue and earnings growth in recent quarters. The good part is that Nvidia can continue counting on these avenues for growth. For instance, the capital expenses of big tech players Microsoft, Amazon, Alphabet, and Meta Platforms are expected to hit $364 billion this year, up from an earlier estimate of $325 billion. All these companies are investing substantially in AI data center infrastructure to bring more AI-focused cloud solutions to customers. The updated capital spending forecast points toward a 63% increase from last year's outlay. A nice chunk of this spending can be expected to be directed toward chips that power AI infrastructure. McKinsey estimates that 60% of AI infrastructure spending is likely to be directed toward chips and computing hardware. Nvidia's addressable market, therefore, is likely to expand. Importantly, the company is the leading player in the AI chip market, with an estimated share of more than 90% at the end of last year. Another factor that's going to give Nvidia stock a nice boost is its access to the Chinese market. The company was frozen out of China in April of this year following export restrictions on the sales of its AI chips to that country. However, Nvidia recently pointed out that it has received assurances it will be able to sell its AI chips to Chinese customers once again. The company has reportedly placed orders for 300,000 China-specific AI chips with its foundry partner Taiwan Semiconductor Manufacturing Company (TSMC). That's in addition to the stockpile of 600,000 to 700,000 existing H20 AI processors that Nvidia is currently sitting on. Nvidia is expected to generate an estimated $15 billion in revenue from sales to Chinese customers in the second half of the year. It is worth noting that Nvidia incurred a $4.5 billion charge in the first quarter of fiscal 2026 on account of restrictions on shipments to Chinese customers. The company also highlighted that its fiscal Q2 revenue would take an $8 billion hit because of those export restrictions. Meanwhile, the aggressive spending on AI infrastructure by governments across the globe is expected to boost Nvidia's annual revenue by $10 billion to $15 billion. As such, don't be surprised to see Nvidia's revenue in the current fiscal year (which will end in January 2026) coast past Wall Street's expectations of $201 billion, which would translate into an increase of 54% from last year. But what about the valuation? Nvidia stock's recent rally has brought its price-to-sales (P/S) multiple to 29 and the price-to-earnings (P/E) ratio to 56. The company needs to keep growing at a faster pace than the market's expectations to justify its rich valuation. The potential growth outlined above suggest it is indeed capable of doing so. The company's planned re-entry into the Chinese market, along with the substantial increase in AI-related spending by big tech companies that have been buying Nvidia's data center processors, could easily help it eclipse consensus expectations in the coming year. The impressive growth Nvidia is expected to deliver is the reason its forward earnings multiples are much lower than the trailing ones. So, growth investors should still consider buying this AI stock, which the most optimistic analyst gives a price target of $250 for the next 12 months. That points toward potential gains of 39% from current levels, and there is a good chance that Nvidia could end up hitting that mark thanks to the healthy spending on AI infrastructure in the coming year. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Where Will Nvidia Stock Be in 1 Year? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
DraftKings Inc. (DKNG) Will Benefit From The Football Season, Says Jim Cramer
We recently published . DraftKings Inc. (NASDAQ:DKNG) is one of the stocks Jim Cramer recently discussed. DraftKings Inc. (NASDAQ:DKNG) is a technology company that primarily provides sports betting services. Its shares have gained 19.5% year-to-date as the firm has benefited from multiple strong quarterly earnings reports and strong annual guidance figures. For instance, DraftKings Inc. (NASDAQ:DKNG)'s jumped in February after the firm increased the low end of its full year guidance to $6.3 billion from an earlier $6.2 billion. In August, the firm reported that its revenue grew by 37% to $1.51 billion. Cramer believes that DraftKings Inc. (NASDAQ:DKNG) will benefit from the football season: 'And then Jason Robins, DraftKings, I mean coming into the football season, coming in hot as opposed to, no I came in cool, I'm sorry.' He discussed DraftKings Inc. (NASDAQ:DKNG) in detail later during the day in Mad Money: 'As we approach football season, things are already looking pretty darn good for DraftKings, one of the nation's largest online sportsbooks. I've been steadfastly bull on this one, you know, just the whole way. After the close, DraftKings reported an impressive quarter, revenue growth accelerating to 37%, better-than-expected earnings, higher-than-expected earnings before interest, taxes, depreciation, and amortization. These results were driven by what DraftKings calls sportsbook-friendly outcomes in the quarter, and the company only reiterated its full-year forecast. But management did say that it now expects to see revenue near the high end of its guidance range. That was good enough to send the stock flying in after-hours trading.' While we acknowledge the potential of DKNG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Moderna, Inc. (MRNA)'s 'Got The Double Whammy,' Says Jim Cramer
We recently published . Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer recently discussed. Moderna, Inc. (NASDAQ:MRNA) has been one of the most ill-fated stocks in 2025. The shares have lost 38% year-to-date as the firm has struggled to diversify away from its mRNA vaccines amidst slipping demand for the products. For instance, Moderna, Inc. (NASDAQ:MRNA)'s full-year revenue guidance of $1.5 billion to $2.2 billion given during its second quarter earnings was lower than the earlier guidance of $1.5 billion to $2.2.5 billion. The reason behind the trimmed guidance was deferred revenue from its COVID vaccines. Cramer discussed Moderna, Inc. (NASDAQ:MRNA) in the context of RFK Jr: 'Hey that's got the double whammy. It's vaccine, got a guy at HHS doesn't like it, they never did anything with the other one.' Copyright: nexusplexus / 123RF Stock Photo The CNBC TV host discussed Moderna, Inc. (NASDAQ:MRNA) in May. Here is what he said: 'There's gotta be some value in Moderna. There just has to be, but I've been against this stock for so long. I first discovered it at 18. Maybe that should be the price target.' While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
